Last reviewed · How we verify

NCT03632057: EFICAZ

Shock Efficacy Study Comparing Fixed Tilt and Fixed Pulse Width in a General Implantable-Cardioverter Population

Completed NA Last updated 7 May 2025
What this trial tests

NA trial testing Fixed Tilt (65%) in Ventricular Arrythmia in 779 participants. Completed in 18 April 2025.

Timeline
6 June 2018
Primary endpoint
18 April 2025
18 April 2025

Quick facts

Lead sponsorAbbott Medical Devices
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment779
Start date6 June 2018
Primary completion18 April 2025
Estimated completion18 April 2025
Sites2 locations across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Abbott Medical Devices — full company profile →

Who can join

18 and older, any sex, with Ventricular Arrythmia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, 1:1 randomized, interventional, multicenter and international trial. Approximately 790 subjects are expected to be enrolled to 40 sites in the south of Europe and Middle East.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Ventricular Arrythmia

Currently open trials in the same condition.

Other Abbott Medical Devices trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03632057.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing